Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Jerónimo C[au]:

Diagnostic and prognostic epigenetic biomarkers in cancer. Costa-Pinheiro P et al. Epigenomics. (2015)

Integrative epigenetic taxonomy of primary prostate cancer. Stelloo S et al. Nat Commun. (2018)

The Emerging Role of Epitranscriptomics in Cancer: Focus on Urological Tumors. Lobo J et al. Genes (Basel). (2018)

Search results

Items: 1 to 50 of 220

1.

VIRMA-Dependent N6-Methyladenosine Modifications Regulate the Expression of Long Non-Coding RNAs CCAT1 and CCAT2 in Prostate Cancer.

Barros-Silva D, Lobo J, Guimarães-Teixeira C, Carneiro I, Oliveira J, Martens-Uzunova ES, Henrique R, Jerónimo C.

Cancers (Basel). 2020 Mar 25;12(4). pii: E771. doi: 10.3390/cancers12040771.

2.

DNA Methylation-Based Testing in Liquid Biopsies as Detection and Prognostic Biomarkers for the Four Major Cancer Types.

Constâncio V, Nunes SP, Henrique R, Jerónimo C.

Cells. 2020 Mar 5;9(3). pii: E624. doi: 10.3390/cells9030624. Review.

3.

The metabolic landscape of urological cancers: New therapeutic perspectives.

Miranda-Gonçalves V, Lameirinhas A, Henrique R, Baltazar F, Jerónimo C.

Cancer Lett. 2020 Mar 3;477:76-87. doi: 10.1016/j.canlet.2020.02.034. [Epub ahead of print]

PMID:
32142920
4.

A Multiplex Test Assessing MiR663ame and VIMme in Urine Accurately Discriminates Bladder Cancer from Inflammatory Conditions.

Monteiro-Reis S, Blanca A, Tedim-Moreira J, Carneiro I, Montezuma D, Monteiro P, Oliveira J, Antunes L, Henrique R, Lopez-Beltran A, Jerónimo C.

J Clin Med. 2020 Feb 24;9(2). pii: E605. doi: 10.3390/jcm9020605.

5.

Digital imaging-assisted quantification of H3K27me3 immunoexpression in luminal A/B-like, HER2-negative, invasive breast cancer predicts patient survival and risk of recurrence.

Fontes-Sousa M, Lobo J, Lobo S, Salta S, Amorim M, Lopes P, Antunes L, de Sousa SP, Henrique R, Jerónimo C.

Mol Med. 2020 Feb 12;26(1):22. doi: 10.1186/s10020-020-0147-5.

6.

Is it "hybrid" or "intermediate"?-more than just a semantic issue in oncocytic renal cell tumors.

Montezuma D, Jerónimo C, Henrique R.

Ann Transl Med. 2019 Dec;7(Suppl 8):S356. doi: 10.21037/atm.2019.09.54. No abstract available.

7.

Targeting the Immune system and Epigenetic Landscape of Urological Tumors.

Lobo J, Jerónimo C, Henrique R.

Int J Mol Sci. 2020 Jan 28;21(3). pii: E829. doi: 10.3390/ijms21030829. Review.

8.

Overexpression of circulating MiR-30b-5p identifies advanced breast cancer.

Estevão-Pereira H, Lobo J, Salta S, Amorim M, Lopes P, Cantante M, Reis B, Antunes L, Castro F, Palma de Sousa S, Gonçalves CS, Costa BM, Henrique R, Jerónimo C.

J Transl Med. 2019 Dec 30;17(1):435. doi: 10.1186/s12967-019-02193-y.

9.

Identification and Validation Model for Informative Liquid Biopsy-Based microRNA Biomarkers: Insights from Germ Cell Tumor In Vitro, In Vivo and Patient-Derived Data.

Lobo J, Gillis AJM, van den Berg A, Dorssers LCJ, Belge G, Dieckmann KP, Roest HP, van der Laan LJW, Gietema J, Hamilton RJ, Jerónimo C, Henrique R, Salvatori D, Looijenga LHJ.

Cells. 2019 Dec 14;8(12). pii: E1637. doi: 10.3390/cells8121637.

10.

The timeline of epigenetic drug discovery: from reality to dreams.

Ganesan A, Arimondo PB, Rots MG, Jeronimo C, Berdasco M.

Clin Epigenetics. 2019 Dec 2;11(1):174. doi: 10.1186/s13148-019-0776-0. Review.

11.

Early detection of the major male cancer types in blood-based liquid biopsies using a DNA methylation panel.

Constâncio V, Nunes SP, Moreira-Barbosa C, Freitas R, Oliveira J, Pousa I, Oliveira J, Soares M, Dias CG, Dias T, Antunes L, Henrique R, Jerónimo C.

Clin Epigenetics. 2019 Dec 2;11(1):175. doi: 10.1186/s13148-019-0779-x.

12.

Expression of EMT-Related Genes CAMK2N1 and WNT5A is increased in Locally Invasive and Metastatic Prostate Cancer.

Carneiro I, Quintela-Vieira F, Lobo J, Moreira-Barbosa C, Menezes FD, Martins AT, Oliveira J, Silva R, Jerónimo C, Henrique R.

J Cancer. 2019 Oct 15;10(24):5915-5925. doi: 10.7150/jca.34564. eCollection 2019.

13.

The Critical Role of Hypoxic Microenvironment and Epigenetic Deregulation in Esophageal Cancer Radioresistance.

Macedo-Silva C, Miranda-Gonçalves V, Henrique R, Jerónimo C, Bravo I.

Genes (Basel). 2019 Nov 14;10(11). pii: E927. doi: 10.3390/genes10110927. Review.

14.

Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers.

Lobo J, Rodrigues Â, Guimarães R, Cantante M, Lopes P, Maurício J, Oliveira J, Jerónimo C, Henrique R.

Cancers (Basel). 2019 Oct 11;11(10). pii: E1535. doi: 10.3390/cancers11101535.

15.

Identification of a biomarker panel for improvement of prostate cancer diagnosis by volatile metabolic profiling of urine.

Lima AR, Pinto J, Azevedo AI, Barros-Silva D, Jerónimo C, Henrique R, de Lourdes Bastos M, Guedes de Pinho P, Carvalho M.

Br J Cancer. 2019 Nov;121(10):857-868. doi: 10.1038/s41416-019-0585-4. Epub 2019 Oct 7.

PMID:
31588123
16.

Circulating MicroRNAs as Biomarkers for Prostate Cancer Detection and Metastasis Development Prediction.

Bidarra D, Constâncio V, Barros-Silva D, Ramalho-Carvalho J, Moreira-Barbosa C, Antunes L, Maurício J, Oliveira J, Henrique R, Jerónimo C.

Front Oncol. 2019 Sep 11;9:900. doi: 10.3389/fonc.2019.00900. eCollection 2019.

17.

Predictive and Prognostic Value of Selected MicroRNAs in Luminal Breast Cancer.

Amorim M, Lobo J, Fontes-Sousa M, Estevão-Pereira H, Salta S, Lopes P, Coimbra N, Antunes L, Palma de Sousa S, Henrique R, Jerónimo C.

Front Genet. 2019 Sep 11;10:815. doi: 10.3389/fgene.2019.00815. eCollection 2019.

18.

Subtyping Lung Cancer Using DNA Methylation in Liquid Biopsies.

Nunes SP, Diniz F, Moreira-Barbosa C, Constâncio V, Silva AV, Oliveira J, Soares M, Paulino S, Cunha AL, Rodrigues J, Antunes L, Henrique R, Jerónimo C.

J Clin Med. 2019 Sep 19;8(9). pii: E1500. doi: 10.3390/jcm8091500.

19.

Corrigendum: Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets.

Miranda-Gonçalves V, Lameirinhas A, Henrique R, Jerónimo C.

Front Genet. 2019 Sep 13;10:784. doi: 10.3389/fgene.2019.00784. eCollection 2019.

20.

XIST-Promoter Demethylation as Tissue Biomarker for Testicular Germ Cell Tumors and Spermatogenesis Quality.

Lobo J, Nunes SP, Gillis AJM, Barros-Silva D, Miranda-Gonçalves V, Berg AVD, Cantante M, Guimarães R, Henrique R, Jerónimo C, Looijenga LHJ.

Cancers (Basel). 2019 Sep 17;11(9). pii: E1385. doi: 10.3390/cancers11091385.

21.

Widening the spectrum of Lynch syndrome: first report of testicular seminoma attributable to MSH2 loss.

Lobo J, Pinto C, Pinheiro M, Lobo F, Sousa N, Lopes P, Looijenga LH, Jerónimo C, Teixeira MR, Henrique R.

Histopathology. 2020 Feb;76(3):486-489. doi: 10.1111/his.13979. Epub 2019 Nov 13. No abstract available.

PMID:
31442315
22.

Histone Recycling by FACT and Spt6 during Transcription Prevents the Scrambling of Histone Modifications.

Jeronimo C, Poitras C, Robert F.

Cell Rep. 2019 Jul 30;28(5):1206-1218.e8. doi: 10.1016/j.celrep.2019.06.097.

23.

In-air production of 3D co-culture tumor spheroid hydrogels for expedited drug screening.

Antunes J, Gaspar VM, Ferreira L, Monteiro M, Henrique R, Jerónimo C, Mano JF.

Acta Biomater. 2019 Aug;94:392-409. doi: 10.1016/j.actbio.2019.06.012. Epub 2019 Jun 12.

PMID:
31200118
24.

Histone variant MacroH2A1 is downregulated in prostate cancer and influences malignant cell phenotype.

Vieira-Silva TS, Monteiro-Reis S, Barros-Silva D, Ramalho-Carvalho J, Graça I, Carneiro I, Martins AT, Oliveira J, Antunes L, Hurtado-Bagès S, Buschbeck M, Henrique R, Jerónimo C.

Cancer Cell Int. 2019 Apr 29;19:112. doi: 10.1186/s12935-019-0835-9. eCollection 2019.

25.

Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer.

Avogbe PH, Manel A, Vian E, Durand G, Forey N, Voegele C, Zvereva M, Hosen MI, Meziani S, De Tilly B, Polo G, Lole O, Francois P, Delhomme TM, Carreira C, Monteiro-Reis S, Henrique R, Abedi-Ardekani B, Byrnes G, Foll M, Weiderpass E, McKay J, Jeronimo C, Scelo G, Le Calvez-Kelm F.

EBioMedicine. 2019 Jun;44:431-438. doi: 10.1016/j.ebiom.2019.05.004. Epub 2019 May 20.

26.

The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell Carcinoma.

Lameirinhas A, Miranda-Gonçalves V, Henrique R, Jerónimo C.

Genes (Basel). 2019 Apr 2;10(4). pii: E264. doi: 10.3390/genes10040264. Review.

27.

Known epigenetic biomarkers for prostate cancer detection and management: exploring the potential of blood-based liquid biopsies.

Constâncio V, Barros-Silva D, Jerónimo C, Henrique R.

Expert Rev Mol Diagn. 2019 May;19(5):367-375. doi: 10.1080/14737159.2019.1604224. Epub 2019 Apr 14.

PMID:
30961397
28.

m6A RNA modification and its writer/reader VIRMA/YTHDF3 in testicular germ cell tumors: a role in seminoma phenotype maintenance.

Lobo J, Costa AL, Cantante M, Guimarães R, Lopes P, Antunes L, Braga I, Oliveira J, Pelizzola M, Henrique R, Jerónimo C.

J Transl Med. 2019 Mar 12;17(1):79. doi: 10.1186/s12967-019-1837-z.

29.

Volatile metabolomic signature of bladder cancer cell lines based on gas chromatography-mass spectrometry.

Rodrigues D, Pinto J, Araújo AM, Monteiro-Reis S, Jerónimo C, Henrique R, de Lourdes Bastos M, de Pinho PG, Carvalho M.

Metabolomics. 2018 Apr 17;14(5):62. doi: 10.1007/s11306-018-1361-9.

PMID:
30830384
30.

GC-MS Metabolomics Reveals Distinct Profiles of Low- and High-Grade Bladder Cancer Cultured Cells.

Rodrigues D, Pinto J, Araújo AM, Jerónimo C, Henrique R, Bastos ML, Guedes de Pinho P, Carvalho M.

Metabolites. 2019 Jan 18;9(1). pii: E18. doi: 10.3390/metabo9010018.

31.

Predicting resistance to endocrine therapy in breast cancer: It's time for epigenetic biomarkers (Review).

Fontes-Sousa M, Amorim M, Salta S, Palma De Sousa S, Henrique R, Jerónimo C.

Oncol Rep. 2019 Mar;41(3):1431-1438. doi: 10.3892/or.2019.6967. Epub 2019 Jan 11. Review.

PMID:
30664168
32.

Epigenetic Mechanisms Influencing Epithelial to Mesenchymal Transition in Bladder Cancer.

Monteiro-Reis S, Lobo J, Henrique R, Jerónimo C.

Int J Mol Sci. 2019 Jan 13;20(2). pii: E297. doi: 10.3390/ijms20020297. Review.

33.

RNA Polymerase II CTD Tyrosine 1 Is Required for Efficient Termination by the Nrd1-Nab3-Sen1 Pathway.

Collin P, Jeronimo C, Poitras C, Robert F.

Mol Cell. 2019 Feb 21;73(4):655-669.e7. doi: 10.1016/j.molcel.2018.12.002. Epub 2019 Jan 10.

34.

Human Germ Cell Tumors are Developmental Cancers: Impact of Epigenetics on Pathobiology and Clinic.

Lobo J, Gillis AJM, Jerónimo C, Henrique R, Looijenga LHJ.

Int J Mol Sci. 2019 Jan 10;20(2). pii: E258. doi: 10.3390/ijms20020258. Review.

35.

The Role of DNA/Histone Modifying Enzymes and Chromatin Remodeling Complexes in Testicular Germ Cell Tumors.

Lobo J, Henrique R, Jerónimo C.

Cancers (Basel). 2018 Dec 20;11(1). pii: E6. doi: 10.3390/cancers11010006. Review.

36.

MSH2 Expression and Resistance to Cisplatin in Muscle-invasive Bladder Cancer: A Mix of Progress and Challenges.

Henrique R, Nunes SP, Jerónimo C.

Eur Urol. 2019 Feb;75(2):251-252. doi: 10.1016/j.eururo.2018.11.014. Epub 2018 Nov 20. No abstract available.

PMID:
30470617
37.

Integrative epigenetic taxonomy of primary prostate cancer.

Stelloo S, Nevedomskaya E, Kim Y, Schuurman K, Valle-Encinas E, Lobo J, Krijgsman O, Peeper DS, Chang SL, Feng FY, Wessels LFA, Henrique R, Jerónimo C, Bergman AM, Zwart W.

Nat Commun. 2018 Nov 21;9(1):4900. doi: 10.1038/s41467-018-07270-2.

38.

The Emerging Role of Epitranscriptomics in Cancer: Focus on Urological Tumors.

Lobo J, Barros-Silva D, Henrique R, Jerónimo C.

Genes (Basel). 2018 Nov 13;9(11). pii: E552. doi: 10.3390/genes9110552. Review.

39.

DNA methylation profiling as a tool for testicular germ cell tumors subtyping.

Costa AL, Moreira-Barbosa C, Lobo J, Vilela-Salgueiro B, Cantante M, Guimarães R, Lopes P, Braga I, Oliveira J, Antunes L, Henrique R, Jerónimo C.

Epigenomics. 2018 Dec;10(12):1511-1523. doi: 10.2217/epi-2018-0034. Epub 2018 Nov 12.

PMID:
30418048
40.

A DNA Methylation-Based Test for Breast Cancer Detection in Circulating Cell-Free DNA.

Salta S, P Nunes S, Fontes-Sousa M, Lopes P, Freitas M, Caldas M, Antunes L, Castro F, Antunes P, Palma de Sousa S, Henrique R, Jerónimo C.

J Clin Med. 2018 Nov 7;7(11). pii: E420. doi: 10.3390/jcm7110420.

41.

Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients.

Moreira-Barbosa C, Barros-Silva D, Costa-Pinheiro P, Torres-Ferreira J, Constâncio V, Freitas R, Oliveira J, Antunes L, Henrique R, Jerónimo C.

Clin Epigenetics. 2018 Oct 29;10(1):132. doi: 10.1186/s13148-018-0564-2.

42.

Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets.

Miranda-Gonçalves V, Lameirinhas A, Henrique R, Jerónimo C.

Front Genet. 2018 Oct 9;9:427. doi: 10.3389/fgene.2018.00427. eCollection 2018. Review. Erratum in: Front Genet. 2019 Sep 13;10:784.

43.

Hybrid oncocytic/chromophobe renal cell tumor: An integrated genetic and epigenetic characterization of a case.

Pires-Luis A, Montezuma D, Vieira J, Ramalho-Carvalho J, Santos C, Teixeira M, Jerónimo C, Henrique R.

Exp Mol Pathol. 2018 Dec;105(3):352-356. doi: 10.1016/j.yexmp.2018.10.008. Epub 2018 Oct 18.

PMID:
30343009
44.

Cell-Free DNA Methylation of Selected Genes Allows for Early Detection of the Major Cancers in Women.

Nunes SP, Moreira-Barbosa C, Salta S, Palma de Sousa S, Pousa I, Oliveira J, Soares M, Rego L, Dias T, Rodrigues J, Antunes L, Henrique R, Jerónimo C.

Cancers (Basel). 2018 Sep 26;10(10). pii: E357. doi: 10.3390/cancers10100357.

45.

Profiling DNA Methylation Based on Next-Generation Sequencing Approaches: New Insights and Clinical Applications.

Barros-Silva D, Marques CJ, Henrique R, Jerónimo C.

Genes (Basel). 2018 Aug 23;9(9). pii: E429. doi: 10.3390/genes9090429. Review.

46.

Prognostic value of histone marks H3K27me3 and H3K9me3 and modifying enzymes EZH2, SETDB1 and LSD-1 in colorectal cancer.

Carvalho S, Freitas M, Antunes L, Monteiro-Reis S, Vieira-Coimbra M, Tavares A, Paulino S, Videira JF, Jerónimo C, Henrique R.

J Cancer Res Clin Oncol. 2018 Nov;144(11):2127-2137. doi: 10.1007/s00432-018-2733-2. Epub 2018 Aug 13.

PMID:
30105513
47.

Testicular germ cell tumors: revisiting a series in light of the new WHO classification and AJCC staging systems, focusing on challenges for pathologists.

Lobo J, Costa AL, Vilela-Salgueiro B, Rodrigues Â, Guimarães R, Cantante M, Lopes P, Antunes L, Jerónimo C, Henrique R.

Hum Pathol. 2018 Dec;82:113-124. doi: 10.1016/j.humpath.2018.07.016. Epub 2018 Jul 21.

PMID:
30041024
48.

Differential expression of E-cadherin and P-cadherin in pT3 prostate cancer: correlation with clinical and pathological features.

Ferreira C, Lobo J, Antunes L, Lopes P, Jerónimo C, Henrique R.

Virchows Arch. 2018 Oct;473(4):443-452. doi: 10.1007/s00428-018-2406-1. Epub 2018 Jul 13.

PMID:
30006753
49.

FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome.

Schrijver W, Schuurman K, van Rossum A, Droog M, Jeronimo C, Salta S, Henrique R, Wesseling J, Moelans C, Linn SC, van den Heuvel M, van Diest P, Zwart W.

Mol Oncol. 2018 Nov;12(11):1884-1894. doi: 10.1002/1878-0261.12353. Epub 2018 Oct 12.

50.

Targeting DNA Methyltranferases in Urological Tumors.

Marques-Magalhães Â, Graça I, Henrique R, Jerónimo C.

Front Pharmacol. 2018 Apr 13;9:366. doi: 10.3389/fphar.2018.00366. eCollection 2018. Review.

Supplemental Content

Loading ...
Support Center